Cannon Global Investment Management’s Minerva Neurosciences NERV Stock Holding History

Cannon Global Investment Management’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$107K	Buy	+17,758	New	+$102K	0.21%	80

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

SSC

Spruce Street Capital New York $416M AUM

Cannon Global Investment Management's NERV Position: Q1 2026 in Review

Cannon Global Investment Management opened a new position in Minerva Neurosciences (NERV) in Q1 2026: 17,758 shares worth $107K. The stake represents 0.21% of the portfolio and ranks #80 among its holdings.

47 funds tracked by Wall St. Rank hold NERV as of Q1 2026.

Cannon Global Investment Management held 17,758 shares of Minerva Neurosciences worth $107K as of Q1 2026.
Minerva Neurosciences was a new Cannon Global Investment Management position in Q1 2026.
Minerva Neurosciences made up 0.21% of Cannon Global Investment Management's portfolio in Q1 2026, its #80 holding.
47 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2026.

Based on Cannon Global Investment Management's 13F filing for Q1 2026, filed 21 Apr 2026.